Neuraxpharm's Strategic Launch in Australia to Enhance Global CNS Treatment Access

Neuraxpharm Expands Internationally with New Australian Affiliate

In a significant move to enhance its global presence, Neuraxpharm Group recently announced the launch of Neuraxpharm Australia, a new affiliate based in Sydney. This initiative is a crucial step in the company's strategy to broaden access to its central nervous system (CNS) treatments beyond Europe, following previous expansions into the Middle East, Brazil, and Mexico.

Neuraxpharm is a renowned specialty pharmaceutical company with a strong focus on CNS disorders, including both psychiatric and neurological conditions. The newly established Australian branch will be spearheaded by Avendran Naidu, who brings over 15 years of experience in commercial sales and leadership within the pharmaceutical sector. Naidu's background includes significant stints at well-known companies such as Jazz Pharmaceuticals and Teva Pharmaceuticals. His appointment signals Neuraxpharm's commitment to creating a robust operational foundation in Australia that can effectively address the local healthcare needs.

The portfolio of treatments that Neuraxpharm Australia plans to commercialize includes Nuvigil® (armodafinil) and Modavigil® (modafinil), both of which have been acquired in late 2024. These medications are aimed at adults suffering from excessive daytime sleepiness associated with narcolepsy, a condition that significantly impacts patients' quality of life. The introduction of these products demonstrates Neuraxpharm's drive to offer innovative solutions to common CNS issues faced by a sizeable patient population in Australia.

Moreover, Neuraxpharm Australia is set to market BRIUMVI® (ublituximab), a recently approved treatment for relapsing-remitting multiple sclerosis (RRMS). The Australian Therapeutic Goods Administration (TGA) granted approval for BRIUMVI in June 2025, and after a favorable recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC), the company is working to ensure that eligible Australian patients can access this novel therapy without delay.

BRIUMVI is noteworthy for its novel mechanism of action as an anti-CD20 monoclonal antibody. It is designed for patients with RRMS and can be administered with just two infusions per year following an initial starting dose. This treatment availability is significant for Australians suffering from this chronic condition, as it may offer an advantageous option compared to existing therapies.

CEO Dr. Jörg-Thomas Dierks emphasized the importance of the Australian market in Neuraxpharm's growth strategy. He stated, "The launch in Australia not only signifies our ongoing commitment to providing a wide range of CNS treatments globally but also shows our dedication to improving the lives of patients. We believe that our existing product portfolio will significantly enhance the treatment landscape available to Australian patients."

Avendran Naidu further added, "As Neuraxpharm sets foot in this exciting market, our goal is to align fully with our global mission to deliver innovative solutions for CNS disorders. Our team will work diligently to make a tangible difference in the healthcare system, focusing on building a passionate workforce that shares our vision for improving patient outcomes."

Neuraxpharm Group has a strong history of innovation, having established its reputation over the past four decades. With a workforce of approximately 1,000 people, the company operates in more than 20 European countries and is actively working to expand its influence globally. Its commitment to addressing unmet patient needs through new product development and strategic partnerships underscores its potential for continued growth within the pharmaceutical industry.

As Neuraxpharm Australia embarks on this new chapter, the company is poised to make significant contributions to the Australian healthcare landscape, potentially transforming the lives of many patients suffering from CNS disorders.

For more information on Neuraxpharm and its offerings, please visit neuraxpharm.com.